FDA-approved GLP-1s like Wegovy, Ozempic, Mounjaro, and Zepbound offer certainties that compounded versions simply cant, including: Consistent, tested ingredients in every dose Manufacturing facilities that meet strict quality standards Pre-filled pens that deliver precise amounts every time Comprehensive tracking of side effects Long-term studies on safety and effectiveness Regular inspections of manufacturing facilities Standardized patient information and warning labels With compounded versions, the risks are very real
Retatrutide simultaneously targets GLP-1, GIP, and glucagon receptors, distinguishing it from currently approved therapies such as semaglutide and tirzepatide
Self-reported nutrition and exercise data
DSIP is classified as an investigational compound
If pharmacy transparency matters to you, Remedy Meds has a gap
With weight loss pills, you can take them on the go and never worry about missing a dose